| F | 0 | F | RN | 4 |
|---|---|---|----|---|
| | | | | |

| Check this box if no |
|-----------------------|
| longer subject to |
| Section 16. Form 4 or |
| Form 5 obligations |
| may continue. See |
| Instruction 1(b). |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses) | | | | | | | | | | |
|--|---|---|---|---|-------------------------------------|---|--|--|--|------------|
| 1. Name and Address of Reporting F TRAVERSA SERGIO | 2. Issuer Name and Ticker or Trading Symbol RELMADA THERAPEUTICS, INC. [RLMD] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | |
| (Last) (First) C/O RELMADA THERAPEU THIRD AVENUE, 9TH FLOO | 3. Date of Earliest Transaction (Month/Day/Year) 12/20/2018 | | | | | _XDirector 10% Owner XOfficer (give title below) Other (specify below) Chief Executive Officer | | | | |
| (Street) NEW YORK, NY 10016 | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | Form filed by More than One Reporting Person | | | |
| (City) (State) | (Zip) | Т | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficia | | | | | | | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any | 3. Transact Code (Instr. 8) | | 4. Securi (A) or D (Instr. 3, | - | of (D) | Owned Following Reported Transaction(s) | 6. Ownership Form: | Beneficial |
| | | (Month/Day/Year) | Code | v | Amount | (A) or (D) | Price | × | Direct (D) or Indirect (I) (Instr. 4) | |

| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
|---|---------------------|
| | espond to the colle |

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| | | | (| e.g., put | s, ca | lls, warra | nts, | options, con | vertible secur | ities) | | | | | |
|-------------|-------------|------------------|--------------------|------------|-------------|--------------|------|--------------|----------------|-----------------|-----------|-------------|----------------|-------------|-------------|
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | | 5. Numbe | r of | 6. Date Exer | cisable and | 7. Title and | Amount | 8. Price of | 9. Number of | 10. | 11. Nature |
| Derivative | Conversion | Date | Execution Date, if | Transact | tion | Derivative | e | Expiration I | Date | of Underly | ing | Derivative | Derivative | Ownership | of Indirect |
| Security | or Exercise | (Month/Day/Year) | | Code | | Securities | | (Month/Day | /Year) | Securities | | Security | | | Beneficial |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | | Acquired | · / | | | (Instr. 3 and | d 4) | (Instr. 5) | ~ | Derivative | 1 |
| | Derivative | | | | or Disposed | | | | | | | | 2 | (Instr. 4) | |
| | Security | | | | | of (D) | | | | | | | 0 | Direct (D) | |
| | | | | | | (Instr. 3, 4 | ŀ, | | | | | | 1 | or Indirect | |
| | | | | | | and 5) | | | 1 | | | | Transaction(s) | < / < | |
| | | | | | | | | | | | Amount | | (Instr. 4) | (Instr. 4) | |
| | | | | | | | | | Expiration | Title | or | | | | |
| | | | | C 1 | * 7 | (1) | | Exercisable | Date | | Number | | | | |
| | | | | Code | V | (A) | (D) | | | | of Shares | | | | |
| Options | | | | | | | | | | | | | | | |
| to | | | | | | | | | | C | | | | | |
| purchase | \$ 1.15 | 12/20/2018 | | Α | | 900,000 | | <u>(1)</u> | 12/20/2028 | Common Stock | 900.000 | \$ 1.15 | 900,000 | D | |
| common | | | | | | , | | | | Stock | , | • • • | , | | |
| stock | | | | | | | | | | | | | | | |
| SIUCK | | | | | | | | | | | | | | | |

Reporting Owners

| Deresting Ormen News (Address | | | Relationships | | | |
|--|----------|-----------|-------------------------|-------|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | |
| TRAVERSA SERGIO C/O RELMADA THERAPEUTICS, INC. 750 THIRD AVENUE, 9TH FLOOR NEW YORK, NY 10016 | Х | | Chief Executive Officer | | | |

Signatures

| /s/ Sergio Traversa | 12/20/2018 | |
|----------------------------------|------------|--|
| Signature of Reporting Person | Date | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.